Your browser doesn't support javascript.
loading
Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome.
Kwok, Wang-Chun; Liang, Bin-Miao; Lui, Macy M S; Tam, Terence C C; Sim, Joycelyn P Y; Tse, Eric W C; Leung, Anskar Y H; Kwong, Yok L; Lie, Albert K W; Ip, Mary S M; Lam, David C L.
  • Kwok WC; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Liang BM; Department of Respiratory Diseases, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China.
  • Lui MMS; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Tam TCC; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Sim JPY; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Tse EWC; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Leung AYH; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Kwong YL; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Lie AKW; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Ip MSM; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
  • Lam DCL; Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
Respirology ; 24(5): 459-466, 2019 05.
Article en En | MEDLINE | ID: mdl-30663178
BACKGROUND AND OBJECTIVE: Bronchiolitis obliterans syndrome (BOS) after haematopoietic stem cell transplantation (HSCT) presents with lung function decline. The pattern of lung function decline after BOS diagnosis could impact prognostication of BOS as a complication after HSCT. The aim of this study was to assess the impact of lung function decline on overall survival (OS) in BOS subjects. METHODS: Subjects with BOS were compared to those without BOS and matched for age, gender, primary diagnoses, conditioning regimes and chronic graft versus host disease. Lung function tests at baseline, at BOS diagnosis and every 3 months after HSCT were evaluated. RESULTS: Of the 1461 subjects undergoing allogeneic HSCT (allo-HSCT) between 1998 and 2015, 95 (6.5%) were diagnosed with BOS. A total of 159 matched HSCT recipients without BOS were identified. A 25% decline in FEV1 within the first 3 months after BOS diagnosis would separate BOS subjects into a subgroup with initial rapid decline and another subgroup with initial gradual decline in lung function. The rapid decline group showed lower subsequent lung function parameters and significantly worse OS compared to the gradual decline group (P = 0.013). CONCLUSION: Post-HSCT BOS subjects with initial rapid lung function decline within 3 months after BOS diagnosis will have significantly poorer lung function and worse OS compared to those with initial gradual decline in lung function after BOS diagnosis. HSCT BOS patients with rapid initial decline in lung function warrant closer monitoring for the development of other post-HSCT complications that could affect their survival.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Respiratoria / Bronquiolitis Obliterante / Trasplante de Células Madre Hematopoyéticas / Pulmón Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Respiratoria / Bronquiolitis Obliterante / Trasplante de Células Madre Hematopoyéticas / Pulmón Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2019 Tipo del documento: Article